NCT07464756 2026-03-11
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
Clinical Trials
216 trialsNCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05451290 2026-02-12
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07353684 2026-01-20
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Beijing Friendship Hospital
Phase 2 Recruiting
NCT07311408 2025-12-31
SHR-2554
China Medical University, China
Phase 2 Recruiting
NCT05235100 2025-12-11
SPARE-02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06925516 2025-11-28
ACADEMY
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06349317 2025-09-29
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase 2 Recruiting
NCT07192848 2025-09-25
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 2 Not yet recruiting
NCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT07105748 2025-08-17
TASK-05
Fudan University
Phase 2 Recruiting
NCT05156970 2025-07-31
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT04560127 2025-07-10
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 2 Active not recruiting
NCT07031154 2025-06-22
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
The First Affiliated Hospital of Xiamen University
Phase 2 Not yet recruiting
NCT04625803 2025-06-17
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Phase 2 Completed
NCT06831175 2025-06-03
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
Phase 2 Recruiting
NCT06429696 2025-05-28
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04072042 2025-05-14
BIOVAS
Ruijin Hospital
Phase 2 Recruiting
NCT06483282 2025-04-15
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT04195828 2025-04-01
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Completed
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT05512481 2025-03-03
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05192798 2025-02-27
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Recruiting
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT06771154 2025-01-13
A-CAPE
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT06308575 2025-01-10
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06764368 2025-01-08
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
Beijing Chest Hospital
Phase 2 Not yet recruiting
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT06418594 2024-12-10
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Beijing 302 Hospital
Phase 2 Recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT06700421 2024-11-22
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis
Chongqing University Cancer Hospital
Phase 2 Active not recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT06632522 2024-10-09
Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
Beijing Tsinghua Chang Gung Hospital
Phase 2 Not yet recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06537505 2024-08-05
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
Beidahuang Industry Group General Hospital
Phase 2 Not yet recruiting
NCT06454578 2024-08-01
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT05412589 2024-07-31
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT04715633 2024-07-09
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06482008 2024-07-01
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06475209 2024-06-26
Adebrelimab + Apatinib in SCLC Maintenance Therapy
Tang-Du Hospital
Phase 2 Recruiting
NCT04834674 2024-06-25
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Recruiting